Objective To examine in a population with a high prevalence of hypertension, the association between six cardiovascular polymorphisms, arterial stiffness and medication use.
Introduction
The renin-angiotensin system (RAS) plays an important role in blood pressure (BP) regulation, cardiovascular cellular growth and remodeling. Many association studies [1] [2] [3] [4] have addressed the possible relationship between variant genes of the RAS with hypertension, left ventricular hypertrophy and myocardial infarction in different populations. In the HIPPOCRATES project (Hypertension: Interaction and Prevalence of POlymorphisms related to Cardiovascular Risk and the Association to Treatment Efficacy Study), three well studied polymorphisms of the RAS were determined, that is, angiotensinogen [AGT (M235T)], angiotensin-converting enzyme [ACE (4656 rpt )] and the angiotensin II type 1 receptor [AGTR1 (A1166C)] polymorphism. Furthermore, three other polymorphisms closely aligned to the RAS were also determined, that is, endothelial nitric oxide synthase [NOS3 (E298D)], G-protein b3 subunit [GNB3 (C825T)] and a-adducin [ADD1 (G460W)]. When HIPPOCRATES was designed, evidence in the literature for the role of these six polymorphisms in the development of cardiovascular disease (CVD) was very promising. HIPPOCRATES utilizes the population of a large general practice, which is located in a region in the southeast of the Netherlands with a high burden of CVD compared with the average of the Netherlands [5] and, therefore, these polymorphisms seemed very relevant for this study population. Finally, in Maastricht, the role of the RAS in the development of CVD has been studied for several years. Consequently, a complete infrastructure was available to determine these polymorphisms accurately and quickly. The overall objective of the HIPPO-CRATES project is to analyze the contribution of the aforementioned polymorphisms to cardiovascular risk. We started off with a cross-sectional data analysis and adopted arterial stiffness as a major surrogate marker for cardiovascular morbidity.
Increased arterial stiffness is an accepted strong independent predictor of cardiovascular risk and is associated with excess cardiovascular morbidity and mortality [6] [7] [8] . Both genetic and environmental factors are responsible for structural changes in the arterial wall and progressive arterial stiffening. An index of central arterial stiffness is carotid-femoral pulse wave velocity (CF-PWV). The measurement of CF-PWV has been considered as the 'gold standard' of arterial stiffness in a recent expert consensus document [9] . It is generally accepted as the simplest noninvasive, robust and reproducible method to determine aortic stiffness, and has been used in many epidemiological studies, demonstrating the predictive value of aortic stiffness for cardiovascular events [10] and all-cause mortality [6, 9] . CF-PWV is mainly enhanced by increasing systolic and pulse pressure (PP) and, therefore, the association between CF-PWV and polymorphisms of the RAS is important to investigate. However, studies on CF-PWV and RAS polymorphisms are rather scarce. The few studies [11] [12] [13] [14] performed thus far showed that genetic variants of the RAS could influence the CF-PWV. Therefore, we hypothesized that in the presence of carriership of one or more mutant alleles of the aforementioned polymorphisms, the CF-PWV values will be higher. In the present study, we investigated the association between the aforementioned six polymorphisms and CF-PWV. Furthermore, we know from the literature that pharmacological treatment is associated with a reduction in CF-PWV [6] . Therefore, we hypothesized that in the presence of carriership of one or more mutant alleles of our six polymorphisms, the CF-PWV will be lower in patients treated with cardiovascular medication. Therefore, we also investigated the influence of cardiovascular medication use on the association between our polymorphisms and CF-PWV.
Methods

Study population
All participants of the HIPPOCRATES project were recruited from one general practice in Kerkrade, the Netherlands between May 2003 and July 2005. This academic general practice takes part in the Registration Network Family Practices, which is a continuous and computerized database. All relevant health problems, including a full medical history of all cardiovascular events, have been registered since 1990 [15, 16] . Medical problems are coded according to the International Classification of Primary Care (ICPC) using the criteria of the International Classification of Health Problems in Primary Care for diagnoses [17, 18] . The general practice in Kerkrade has a list of approximately 4400 patients, among whom are more than 2300 patients of 40 years and older. The practice is located in a region with a high burden of CVD and, therefore, it has well implemented cardiovascular consulting hours. For many years, the practice nurses have conducted special cardiovascular consulting hours, to which patients are invited at least once every 3 months. For the HIPPOCRATES project, all known patients aged at least 40 years with CVD or hypertension, irrespective of their medication use, were invited. From the group with neither known CVD nor established hypertension, but with other cardiovascular risk factors, that is, smoking, alcohol, diabetes mellitus, hypercholesterolemia, overweight including obesity, a random 1 : 3 sample was taken. Of all 'healthy' individuals (neither CVD, nor hypertension nor other cardiovascular risk factors), a random 1 : 3 sample was also taken. The initial classification was validated by a thorough assessment of the patients' records combined with additional measurements of risk factors for all patients. The total HIPPOCRATES population consisted of 803 patients (382 men, 421 women). During their first visit, patients were asked permission to measure the PWV over the CF-PWV and the carotid-radial pulse wave velocity (CR-PWV) route. Included patients did not differ in characteristics from those who did not consent (185 patients). PWV data of 22 patients were not included owing to premature withdrawal from the study (five patients) or to poor quality of the measurements (17 patients), though again, these patients did not differ with respect to their characteristics. Additionally, 21 patients were excluded owing to the diagnosis of peripheral arterial occlusive disease. For the present study, 575 patients were included, 273 men and 302 women. The study was approved by the Medical Ethics Committee of the Maastricht University Medical Center, Maastricht, The Netherlands. All patients gave written informed consent to participate in the study.
Clinical data collection
All clinical measurements in the HIPPOCRATES project were performed in the practice by one of the authors (A.P., first measurement) and a nurse practitioner (second, third and fourth measurement with in between periods of 3 months). The nurse practitioner measured weight and BP. All persons were questioned on their smoking behavior. Weight and height were measured. BMI was calculated as body weight divided by squared height. BMI values at least 27 were considered to be too high. The size of the waist was measured. BP and heart rate were measured three times per visit, after 10 min rest in sitting position, using a sphygmomanometer. Fasting blood samples were drawn to determine serum creatinine, total cholesterol, low-density lipoprotein-cholesterol (LDL-c), high-density lipoprotein-cholesterol (HDL-c), serum triglycerides and glucose levels and were analyzed in one regional laboratory. Microalbuminuria was determined semiquantitatively in a first morning urine sample.
Treatment status
The computerized medication lists were analyzed for antihypertensive, hypolipidemic, antiplatelet and antidiabetic medication. Furthermore, all persons were questioned about their medication use at the start of the study. Cardiovascular medication was based on the anatomical therapeutic classification (ATC) and defined as having at least one prescription of antihypertensive (ATC level 2: C02, C03, C04, C07, C08, C09), hypolipidemic (ATC level 2: C10), or antiplatelet (ATC level 5: B01AC) medication in the selected study period. This definition was chosen, as these drugs are most frequently prescribed for the prevention of CVD in primary care. Antidiabetics were defined as having at least one prescription of A10 (ATC level 2) in the study period.
Definitions
Hypertension was defined as a systolic blood pressure (SBP) at least 140 mmHg, diastolic blood pressure (DBP) at least 90 mmHg or both according to the Guidelines for Hypertension specified by the European Society of Hypertension [19] . PP was calculated as the difference between SBP and DBP. The presence of dislipidemia was defined as total cholesterol to HDL-c ratio exceeding 4.0. Diabetes mellitus was considered to be present in case of fasting plasma glucose levels above 6.9 mmol/l. Creatinine values higher than 115 mmol/l (men) or 107 mmol/l (women) were considered to be a risk factor for CVD. Creatinine clearance was calculated by the Cockcroft-Gault formula [20] . Microalbuminuria was defined as albumin excretion above 20 mg/l.
Arterial stiffness
The PWV measurements were performed at the circulation laboratory of the Department of Internal Medicine of the Maastricht University Medical Center, Maastricht, The Netherlands. PWV was recorded by Complior (Artech, Pantin, France), a PWV measurement system for arterial stiffness evaluation. This system gives an automated measurement of PWV for two arterial segments simultaneously, with dedicated pulse wave sensors [9] . This system determines the transit time the wave of dilatation (propagated in the arterial wall as a result of the pressure wave generated by contraction of the left ventricle) takes to arrive at a site over a known distance [9] . After resting in a supine position for 15 min in a quiet, temperature-controlled room, patients were examined by a trained investigator (A.P.), who obtained PWV measurements in two arterial segments simultaneously, that is carotid-radial and carotid-femoral. In order to enhance reproducibility, PWV was measured four times and mean values were calculated for both arterial segments [9] .
CF-PWV evaluates a mixed elastic and muscular segment of the arterial tree, whereas the CR-PWV evaluates a predominantly muscular segment. The effect of aging has been shown to be more pronounced in the proximal, more elastic, and less muscular arteries [21] . Expressing PWV as a ratio of the CF/CR-PWV improves the relationship with age, as has been demonstrated by Cameron et al. [22] . It is for this reason that we expressed our data as such, using the ratio of CF-PWV to CR-PWV. A CF-PWV above 12 m/s and a CF/CR ratio above 1 were considered as threshold values [7] . Consequently, values above these thresholds were considered to be increased. All patients were measured at the same period of the day, that is the afternoon.
Genetic analyses
The various polymorphisms were determined at the Cardiovascular Genotyping (CAGT) laboratory of the Department of Internal Medicine of the University Hospital Maastricht. DNA was extracted from whole blood with the use of the QIAmp Blood Kit (Qiagen Inc., Venlo, The Netherlands). Genotyping of the AGTR1 (A1166C), AGT (M235T), ACE (4656 rpt ), NOS3 (E298D), GNB3 (C825T) and ADD1 (G460W) polymorphisms was performed with a multiplex singlebase extension (SBE) assay (Multiplex SNaPshot, Applied Biosystems, Foster City, California, USA) similar to previously published protocols [23] . Briefly, in the first stage, a multiplex PCR is carried out to amplify the gene fragments that contain the polymorphisms. In the second stage, the polymorphic positions are interrogated by a SBE reaction using fluorescently labeled dideoxyribonucleotide triphosphates (ddNTPs). The oligos used for the SBE have specific lengths, varying from 22 to 50 nt. After the SBE assay, the fragments are size resolved on an ABI3100 Genetic Analyser (Applied Biosystems); the size of the peaks identifies the locus (e.g. ADD1) and the color of the peak(s) identifies the genotype (e.g. Gly/ Trp). Raw data were analyzed with Genescan Analysis software (v 3.7) (Applied Biosystems), then genotypes were scored independently by two researchers and entered in the database. In 27 patients, a second analysis was necessary to obtain all the genotypes. The ACE (I/D) polymorphism was determined by detecting ACE 4656þCT observed on the SNaPshot as ACE (4656 rpt ). The use of this SNaPshot method does not allow the direct determination of the insertion/deletion polymorphism. The ACE 4656þCT polymorphism in the 3 0 -untranslated region of the ACE gene consists of a repetition of two or three CT dinucleotides and is in complete linkage disequilibrium with ACE (I/D) [24, 25] . The multiplex assay was validated on a set of 100 DNA samples that had previously been genotyped with an alternative technique; this technique concerned a multilocus genotyping assay for candidate markers of CVD risk (Roche Molecular systems Inc., Alameda, California, USA) and has been described in detail previously [26] . Only four samples gave a discordant result for the NOS3 polymorphism. All other genotypes were concordant.
Polymorphisms
In short, the presumed function of the included polymorphisms is as follows. Patients homozygous for the C allele of the AGTR1 polymorphism have increased sensitivity to angiotensin II (AngII) and this may, in combination with the DD genotype of the ACE (I/D) polymorphism, lead to an increased risk of cardiovascular complications [27, 28] . The T allele of the AGT polymorphism is associated with high plasma levels of AGT and increased responsiveness to AngII [4] . In the presence of a 2-allele of the ACE 4656þCT polymorphism, comparable with the D allele of the I/D polymorphism, increased ACE levels have been found, which have been associated with an increased risk for cardiovasular complications [2] . The NOS3 (E298D) polymorphism is associated with reduced nitric oxide production in endothelial cells of the arterial wall, inducing elevation of the arterial pressure [26, 29] . The T allele of the GNB3 (C825T) polymorphism is associated with increased intracellular signal transduction and this leads to stimulation of the Na þ /H þ exchanger [30] . The ADD1 (G460W) polymorphism is of interest because the mutant allele is also associated with increased Na þ transport, though here the Na þ /K þ exchanger is stimulated [31] . Both polymorphisms are associated with chronic volume expansion and, consequently, with related cardiovascular complications [31, 32] .
Statistical analyses
Statistical analyses were performed by using SPSS statistical software, version 14.0 (SPSS, Inc., Chicago, Illinois, USA). A P value of 0.05 or less was considered statistically significant. Genotype and allele frequencies were calculated to test the Hardy-Weinberg equilibrium. Furthermore, allele frequencies were analyzed using chi-square tests.
Multivariate linear regression analyses
Because of the skewed distribution of the CF/CR ratio, log transformation was applied to achieve normality for further analyses. Univariate and multivariate linear regression analyses were performed to evaluate the relationship between polymorphisms and CF/CR ratio. For that purpose, dummy variables were created using the homozygous wild-type genotype as reference category. Age and sex, both demographic variables, were incorporated in both the univariate and the multivariate linear regression analyses. As indicated, we selected control individuals from different groups. Therefore, in the regression analyses, we had to adjust for this selection and dummy variables had to be created using the normotensive group without cardiovascular risk factors as the reference category. Adjustment for potential confounders was performed by incorporating age, sex, dislipidemia, cardiovascular medication and PP into these models (enter procedure). The simultaneous contribution of the six polymorphisms to the prediction of increased CF/CR ratio was determined, using the overall F test. If two or more polymorphisms reached statistical significance, interactions (effect modification) between two polymorphisms with respect to CF/CR ratio were assessed. Again linear regression analysis was used, in which the alleles at risk, the interaction term between the alleles and the other covariates were incorporated. If an interaction became statistically significant, the model was explored further.
If one or more polymorphisms reached statistical significance, interaction between cardiovascular medication use and the relevant polymorphism with respect to CF/CR ratio was assessed. Again, linear regression analysis (method:enter) was used, in which the alleles at risk, the interaction between cardiovascular medication use and the alleles and the other covariates were incorporated. If an interaction became statistically significant, the model was explored further.
Results
Characteristics of the participants
Characteristics of the study population are summarized in Table 1 . Most patients were overweight hypertensives with dislipidemia. There were slightly more women than men, and their mean age was 60 years. Overall, 30% of the patients had a CF-PWV above 12 m/s and more than 60% of the patients had a CF/CR ratio above 1.
Allele frequencies
Genotype and allele frequencies of all polymorphisms were in Hardy-Weinberg equilibrium. For all six polymorphisms, no statistically significant differences in allele frequencies were found.
Arterial stiffness, cardiovascular polymorphisms and treatment status
Stepwise regression analyses identified age, sex, dislipidemia, cardiovascular medication use and PP as significant covariables for the relationship between the six polymorphisms and the CF/CR ratio. In the univariate linear regression analyses (Table 2) , an association was found between carriership (dominant model) of the C allele of AGTR1 and the CF/CR ratio (P ¼ 0.014). However, in the multivariate linear regression analyses (Table 2) , the simultaneous contribution of the six polymorphisms to the change in the CF/CR ratio (overall F test) reached no statistical significance (P ¼ 0.107). We assessed an independent statistically significant association between AGTR1 and the CF/CR ratio (P ¼ 0.011). It appeared that the CF/CR ratio decreased by 4% if patients were carriers of the C allele of AGTR1. For all other polymorphisms, carriership of the mutant allele was not statistically significantly associated with the CF/CR ratio. Analyses based on the assessments of the CF-PWV showed virtually the same results (data not shown).
When comparing the CF/CR ratios for the whole study population, as well as for patients that were on cardiovascular medication, a statistically significant trend (P ¼ 0.04) was found for the ratio to decrease with the number of C alleles (codominant model, Fig. 1) . Furthermore, we performed an explorative analysis (dominant model) to evaluate the influence of cardiovascular medication use on the association between the AGTR1 (A1166C) polymorphism and the CF/CR ratio. The interaction between cardiovascular medication use and the AGTR1 (A1166C) polymorphism was statistically significant (P ¼ 0.04). Because the interaction term was statistically significant, we performed a stratified analysis to explore the direction of the effect. The results of these analyses are presented in Fig. 2 . Figure 2 shows that in patients treated with cardiovascular medication, the C allele of AGTR1 polymorphism is also significantly associated with a lower CF/CR ratio [P ¼ 0.011, overall F test (P ¼ 0.078)], whereas no statistically significant association was observed in untreated patients. Posthoc analyses of the different medication groups separately showed for all groups a protective association of the C allele of AGTR1 with the CF/CR ratio. However, only for the b-blockers was statistical significance reached (P ¼ 0.006), overall F test (P ¼ 0.03).
Discussion
In the present study, we found a statistically significant protective association of the C allele of AGTR1 (A1166C) 
Values are given as mean AE SD or as number of patients (with corresponding percentages in brackets); creatinine clearance by the Cockcroft-Gault formula. CF/CR ratio, carotid-femoral to carotid-radial pulse wave velocity ratio; CF-PWV, carotid-femoral pulse wave velocity; CR-PWV, carotid-radial pulse wave velocity; HDL, high-density lipoprotein; LDL, low-density lipoprotein. Table 2 Linear regression model for six polymorphisms (dominant model) and carotid-femoral to carotid-radial ratio for all patients Carotid-femoral to carotid-radial pulse wave velocity ratio (logtransformed values) in the whole study population, according to the AGTR1 (A1166C) polymorphism. The observed differences in CF/CR ratio are statistically significant (P ¼ 0.04). For each allele combination, the number of patients is depicted. Values are unadjusted means AE SE.
with PWV (P ¼ 0.011) for patients in a primary care population. This effect was independent of age, sex, dislipidemia, cardiovascular medication use and PP. Explorative analyses showed furthermore that patients treated with cardiovascular medication had a significantly lower CF/CR ratio in the presence of C alleles, of which the latter seemed to show a dose-allele effect.
Arterial stiffness, angiotensin II type 1 receptor polymorphism and treatment status AngII plays a key role through the AGTR1 in BP regulation, cardiovascular cellular growth and remodelling. So, the AGTR1 polymorphism of the AGTR1 gene is, at least theoretically, a good candidate for an association with stiffening of the large arteries by inducing vascular remodelling. Indeed, our finding of an independent association of the AGTR1 (A1166C) polymorphism with CF-PWV is in accordance with the results of three previous studies [11, 12, 14] . We found, like the study performed by Gardier et al. [14] , but in contrast to Benetos et al. [11, 12] , that AA homozygous patients had a higher CF-PWV. Participants of our study were mainly overweight hypertensive patients from a primary care practice, whereas the patients in the study of Gardier et al. [14] were retrieved from a hospital cardiology department with mainly severe or resistant hypertension. Benetos et al. [11, 12] included in his study never-treated hypertensive patients, retrieved from a hospital hypertension department. In our study population, mainly antihypertensive treated individuals were selected. So, it can be argued that antihypertensive medication decreased arterial stiffness by a pressuredependent effect, in particular in those patients with an increased CF-PWV in the untreated situation [33] .
Our analyses seem to confirm this. Moreover, posthoc analyses of the different medication groups separately pointed in the same direction for all regression coefficients, that is, a protective association of the C allele of AGTR1 with the CF/CR ratio. However, only for the b-blockers was statistical significance reached. One might argue that our results were confounded by disease severity; patients with most prominent risk factors were treated more intensively. First, our results were independent of dislipidemia and PP. Second, the treatment intensity did not seem to play a role, as the number of drug classes was not significantly different among treated patients with the AA genotype versus those with the C allele carriership.
The assessed association of the AGTR1 (A1166C) polymorphism needs further explanation. In a recent report, left ventricular cardiac stiffness was increased in homozygous A-allele carriers compared with C Ã (AC þ CC) carriers in hypertensive patients, suggesting that chronic exposure to AngII might induce, in hypertensive patients with the A allele, an imbalance between collagen synthesis and degradation [34] . An alternative explanation for the lower CF/CR ratio in the C-allele carriers might be that the C allele is associated with an increased AngIinduced nitric oxide release, mediated in endothelial cells by AGTR1 receptors and, thus, counterbalancing the direct vasoconstrictive effect of AngII on the smooth muscle [35, 36] . However, such hypotheses require further confirmation in other studies.
Some limitations of the present study should be acknowledged. First, the AGTR1 (A1166C) polymorphism is probably not a functional one, because the AGTR1 polymorphism is located in a noncoding region of the chromosome 3q22 [37] and, therefore, the amino acid sequence of the receptor is not altered. It is possible that the AGTR1 polymorphism is in linkage disequilibrium with an unidentified functional variant of the AGTR1 gene, or, alternatively, the polymorphism could be in linkage disequilibrium with a nearby gene, which is responsible for the association with the CF/CR ratio. Nevertheless, others and we have shown that this polymorphism, that is, the C allele, is associated with an increased sensitivity to AngII [28] . Another limitation of this study is that we compared a recessive model of inheritance of the A allele in AA versus C Ã (AC þ CC) carriers. This choice was made on the basis of results of other studies, though we realize this choice is arbitrary. Another approach would have been to analyze our data with a codominant model, therefore, we have shown the analysis presented in Fig. 1 . Finally, we realize that our design is cross-sectional. This implies two major problems. First of all, the CF-PWV is influenced by cardiovascular medication, and second, channeling plays an important role, that is, the most severe cardiovascular patients are treated more intensively. In a cross-sectional Carotid-femoral to carotid-radial pulse wave velocity ratio for carriership of the AGTR1 (A1166C) polymorphism. The observed difference in CF/CR ratio between patients treated with cardiovascular medication with AA genotype and treated carriers of the C allele is statistically significant (P ¼ 0.011). For each allele combination, the number of patients is indicated. Values are unadjusted means AE SE.
design, the contribution of these two factors cannot be distinguished and, therefore, our findings should be viewed as hypothesis generating and require further confirmation in prospective epidemiological studies. Nevertheless, our study has also a unique aspect. As compared with previous studies, we used a relatively unselected population from primary care. Results from studies among unselected populations may lead to better cardiovascular risk stratification.
In conclusion, this study shows that in this population a statistically significant relationship exists between the AGTR1 polymorphism, arterial stiffness and cardiovascular medication. Even though the underlying mechanisms have yet to be elucidated, these data suggest that the AGTR1 gene, or a yet unidentified gene locus in linkage disequilibrium with AGTR1 A1166C polymorphism, may be a genetic determinant of arterial stiffness.
